The buzz around San Francisco was unmistakable earlier this month as J.P. Morgan’s 44th Annual Healthcare Conference once again transformed Union Square into the gravitational center of the global healthcare investment community. The conference drew more than 8,000 registered attendees and more than 500 presenting companies, while countless others participated in the dense network of parallel meetings, unofficial events and offsite gatherings that define the week, including ours.
Despite the familiar energy, the atmosphere felt balanced; active, but not overwhelming. Many smaller funds curbed travel budgets, reflecting broader cost discipline and comfort with virtual engagement. Yet those who came were deliberate with their questions pointed, their agendas clear and their time intentional. The City by the Bay again proved why this annual confab remains the most important stage for networking, partnering, investing and dealmaking across the healthcare landscape.
A Brighter Mood, A Sharper Focus
The bright skies under which this year’s conference unfolded matched the mood inside. With easing uncertainty around MFN pricing and tariffs, investors approached the week with optimism and a heightened focus on innovation. Artificial intelligence, metabolic health, China and emerging therapeutic modalities dominated discussions, highlighting where both curiosity and capital are heading next.
While the number of headline‑making deals was limited, enthusiasm ran deep for a robust year of transactions. The tone wasn’t exuberant, but it was confident, confirming the momentum the sector has enjoyed since a sharp rebound began mid last year.
Our view of the industry’s tone was affirmed by the late-January release of Endpoints’ Q1 2026 Biopharma Sentiment Index, which showed a meaningful jump to 90 versus 78 in the prior quarter, with all 10 core measures improving. This shift was against the backdrop of a 12-year low in U.S. consumer confidence. That said, 100 is considered the Index’s neutral benchmark.
Successful Alliance Advisors IR Offsite Event
This upbeat sentiment extended to Alliance Advisors IR’s own activities throughout the week. With our offsite event having now completed its 22nd year, we arranged some 300 investor meetings on behalf of 14 clients. Interactions spanned a diverse range of participants, from microcap funds and healthcare specialists to leading institutions selectively rebuilding sector exposure.
In an environment where virtual dialogue has become common, these high‑impact in‑person discussions were a clear reminder that effective investor access still depends on showing up. For emerging and under‑followed companies in particular JPM week remains a critical platform for visibility, credibility and relationship building.
Investor sentiment across our clients’ meetings was unmistakable. Companies are expected to demonstrate financial discipline and runway visibility. Investors are prioritizing tangible progress focusing on clinical, regulatory or commercial milestones over abstract promises or ambitious narratives.
Improving IPO Window, Increasing M&A Activity
There were notably more discussions with investment bankers about the reopening of the IPO window, which is returning in 2026 in a far more selective, fundamentals‑driven form than the 2020–2021 boom. After a decade‑low number of biotech IPOs in 2025, analysts expect the rebound to be supported by a backlog of companies that delayed listings and a 2025 recovery in biotech indices. Deals like Aktis Oncology’s sizable January 2026 IPO were seen as early signals of opportunity for companies with late‑stage or de‑risked pipelines, especially in oncology, metabolic health, precision medicine and respiratory disease.
As usual, M&A was a central theme throughout the conference. Although few transactions were announced during the week – and it’s a bit naïve to think such announcements can be timed to coincide with a conference – conversations among management teams, investors and advisors repeatedly pointed to a growing pipeline of acquisitions, licensing deals and structured transactions. Banks worked aggressively to position themselves for this future deal flow, emphasizing deep sector expertise, durable client relationships and early involvement in strategic decision‑making by issuers. They also devoted more energy to identifying differentiated assets earlier in their lifecycle, particularly among micro‑ and small-cap companies on the belief that these could become the next wave of strategic targets.
Setting the 2026 Sector Outlook
If conversations at JPM26 set the tone for the year ahead, healthcare looks poised for renewed strength, extending the large‑ and mid‑cap rally that began in mid‑2025. With interest rates expected to ease and expectations for an active year of fundraising and deals, investors increasingly view the sector not just as defensive, but as a growth engine driven by innovation and fundamentals. This heightened focus on the sector provides a useful view for assessing how each segment is poised for the year ahead:
- Large‑cap pharma and medtech remain positioned for steady growth through new product cycles and acquisitions.
- Mid‑caps stand out for improving fundamentals and continued interest among strategics, though volatility persists.
- Micro‑ and small‑caps offer higher risk but greater reward as funding conditions improve, and acquirers seek promising assets and even new technologies to replenish pipelines.
Underpinning this optimism are the tailwinds of aging populations, the rising prevalence of chronic diseases and the expanding application of AI across research, operations and clinical development.
Closing Perspective
After several turbulent years for healthcare equities, JPM26 signaled a sector full of promise. For disciplined investors, 2026 presents genuine opportunity through focus, selectivity and sustained performance.
Alliance Advisors IR and our team of seasoned healthcare professionals are proud to help clients navigate this shifting terrain by once again facilitating meaningful connections, sharpening messaging and positioning companies for sustained value creation. We invite you to learn more about our healthcare practice and how we support companies navigating the public markets.